Compare AEVA & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEVA | KURA |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.0M | 830.1M |
| IPO Year | N/A | 2015 |
| Metric | AEVA | KURA |
|---|---|---|
| Price | $12.54 | $8.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $26.50 | ★ $26.88 |
| AVG Volume (30 Days) | ★ 2.1M | 1.3M |
| Earning Date | 01-01-0001 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,883,000.00 |
| Revenue This Year | $87.55 | $88.72 |
| Revenue Next Year | $70.04 | $60.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.52 | $5.41 |
| 52 Week High | $38.79 | $12.49 |
| Indicator | AEVA | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 47.78 |
| Support Level | $12.32 | $7.50 |
| Resistance Level | $13.40 | $8.70 |
| Average True Range (ATR) | 1.06 | 0.34 |
| MACD | 0.02 | 0.14 |
| Stochastic Oscillator | 54.90 | 79.44 |
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.